Deeg HJ, O’Donnell M, Tolar J, Agarwal R, Harris RE, Feig SA, Territo MC, Collins RH, McSweeney PA, Copelan EA, Khan SP, Woolfrey A, and Storer B. Optimization of Conditioning for Marrow Transplantation from Unrelated Donors for Patients with Aplastic Anemia After Failure of Ummunosuppressive Therapy.  Blood. 108:1485-1491 2006.

Lopez F, Parker P, Nademanee A, Rodriguez R, Al-Kadhimi Z, Bhatia R, Cohen S, Falk P, Fung H, Kirschbaum M, Krishnan A, Kogut N, Molina A, Nakamura R, O’Donnell M, Popplewell L, Pullarkat V, Rosenthal J, Sahebi F, Smith E, Snyder D, Somlo G, Spielberger R, Stein A, Sweetman R, Zain J, and Forman SF. Efficacy of Mycophenolate mofetil in the Treatment of Chronic Graft-versus Disease. Biology of Blood and Marrow Transplantation. 11:307-313 2005.

Rodriguez R, Parker P, Nademanee A, Smith D, O’Donnell MR, Stein A, Snyder DS, Fung HC, Krishnan A, Popplewell L, Cohen S, Somlo G, Angelopoulou M, Al-Kadhimi Z, Falk PM, Spielberger r, Kogut N, Sahebi F, Senitzer D, Slovak m, Schriber J, Forman SJ. Cyclosporine and mycophenolate mofetil prophylaxis with Fludarabine and Melphalan conditioning for unrelated donor transplantation: a prospective study of 22 patients with hematologic malignancies. Bone Marrow Transplantation 33 (11): 1123-1129 June 2004.

Stein A, O’Donnell MR, Parker P, Spielberger R, Nademanee A, Bhatie R, Snyder s, Krischbaum M, Pullarkat V, Kogut N, Vora N, Land J, Dagis A, Palmer and Forman SJ. Analysis of long term outcome in autologous stem cell transplant (ASCT) for acute myelogenous leukemia (AML) in first remission (CR1) – A 15 year experience. Presented at ASH 2003.

Somlo G, Yamamoto N, Carter N, O’Donnell MR, Snyder D, Sahebi F, Krishnan A, Fung H, Stein A, Spielberger R, Schriber j, Alvarnas J, Chow W, Nademanee A, Zain, Jasmine, Forman, SJ. High complete response rate is associated with improved progression-free and overall survival in 104 patients with multiple myeloma, treated with tandem cycle high-dose Melphalan and busulfan/cytoxan, and maintenance interferon alpha-2 (IF) with, or without thalidomide (Thai). Blood 102 (11): 985A-986A November 2003.

A Krishnan MD, Chang K, Fung HC, O’Donnell M, Bhatia R, Spielberger R, Pullarkat V, Stein A, Kogut N, Kirschbaum M, Bolotin E, SarkodeeAdoo C, Dagis A, Cheng N, and Forman SJ. Impact of allogeneic stem cell transplantation (ASCT) on Outcome of Biphenotypic Acute Leukemia (BAL).

M Kirschbaum, O’Donnell M, Spielberger R, Bhatia R, Pullarkat V, Stein A, Kogut N, Bolotin E, Chang K, Land J, Sarkodee-Adoo C, Snyder D, Forman SJ. Peripheral blood stem cells vs bone marrow for matched sibling transplant in AML and ALL remission. Submitted to ASH December 2004.

A Stein, M O’Donnell, A Nademanee, P Parker, H Fung, R Spielberger, N Kogut, D Snyder, C Sarkodee-Adoo, D Smith, A Dagis, D Senitzer, N Vora, K Chang, F Sahebi, R Rodriguez, L Popplewell, ML Slovak, JC Alvarnas, JR Schriber, SJ Forman: Improved disease free survival (DFS) after transplantation of peripheral blood stem cells (PBSCs) as compared with bone marrow from HLA-identical unrelated donor in patients with acute myelogenous leukemia (AML).  Blood; 102: 1773a, 2003.

Chang KL, O’Donnell MR, Slovak M, Dagis A, Arber D, Niland J, Forman SJ: Primary myelodysplasis occurring in adults under 50 years old: A clinicopathologic study of 52 patients. Leukemia, December 2001.

Stein AS, O’Donnell MR, Slovak ML, Snyder DS, Nademanee A, Parker P, Molina A, Somlo G, Kashyap A, Fung HC, Krishnan A, Rodriguez R, Popplewell L, Cohen S, Falk PM, Kogut NM, Sahebi F, Spielberger RT, Wang S, Dagis A, Vora N, Arber DA, Niland JC, Forman SJ: Interleukin-2 following autologous stem cell transplant for adult patients with acute myeloid leukemia in first complete remission. J Clin Oncol, 2003;15:21: 615-23.

Somlo G, Chow W, Hamasaki V, Leong L, Margolin K, Morgan R Jr, Sniecinski I, Frankel P, Reardon D, Longmate J, Raschko J, Shibata S, O’Donnell MR, Smith E, Tetef M, Forman SJ, Yun Y, Molina A, Doroshow JH: Tandem-cycle high-dose Melphalan and Cisplatin with peripheral blood progenitor cell support in patients with breast cancer and other malignancies. Biology of Blood and Marrow Transplantation 7:284-293, 2001.

Storb R, Blume KG, O’Donnell MR, Chauncey T, Forman SF, Deeg HJ, Hu WW, Appelbaum FR, Doney K, Flowers M, Sanders J, Leisenring W: Cyclophosphamide and antithymocyte globulin to condition patients with aplastic anemia for allogeneic marrow transplantations: The experience in four centers. Biology of Blood and Marrow Transplantation 7:39-44, 2001.

Bhatia S, Louie AD, Bhatia R, O’Donnell MR, Fung HC, Kashyap A, Krishnan A, Molina A, Nademanee A, Niland JC, Parker PA, Snyder DS, Spielberger R, Stein A, Forman SJ: Solid cancers after bone marrow transplantation. Journal of Clinical Oncology 19:2, 2001:pp464-471.

Chao NF, Snyder DS, Fain M, Wong RM, Niland JC, Negrin RS, Long GD, Hu WW, Stockerl-Goldstein KE, Johnston lJ, Amylon MD, Tierney DK, O’Donnell MR, Nademanee AP, Parker P, Stein A, Molina A, Fung HC, Kashyap A, Kohler S, Spielberger R, Krishnan A, Rodriguez R, Forman SJ, Blume KG: Equivalence of 2 effective graft-versus-host disease prophylaxis regimens: Results of a prospective double blind randomized trial. Biology of Blood and Marrow Transplantation. 6:254-261, 2000.

Nademanee A, Molina A, Dagis A, Snyder D, O’Donnell MR, Parker P, Stein A, Smith E, Planas I, Kashyap A, Spielberger R, Fung HC, Krishnan A, Bhatia R, Wong KK, Somlo G, Margolin K, Chow W, Sniecinski I, Vora N, Slovak M, Niland JC, Forman SJ: Autologous stem-cell transplantation for poor-risk and relapsed intermediate and high-grade non-Hodgkin’s lymphoma. Clinical Lymphoma, 2000, pg 46-54.

This is a partial list. Full publications list available upon request. Information on this page may be self-reported and is subject to change at any time. Last updated: 07/08.